{"id":3079,"date":"2025-03-05T16:45:40","date_gmt":"2025-03-05T13:45:40","guid":{"rendered":"https:\/\/dmdwarrior.com\/?p=3079"},"modified":"2025-03-07T12:54:07","modified_gmt":"2025-03-07T09:54:07","slug":"pepgen-temporarily-pauses-exon-51-skipping-study","status":"publish","type":"post","link":"https:\/\/dmdwarrior.com\/fr\/pepgen-temporarily-pauses-exon-51-skipping-study\/","title":{"rendered":"PepGen suspend temporairement l&#039;\u00e9tude sur le saut de l&#039;exon 51"},"content":{"rendered":"<p class=\"wp-block-paragraph\">PepGen, une soci\u00e9t\u00e9 de biotechnologie en phase clinique qui fait progresser la prochaine g\u00e9n\u00e9ration de th\u00e9rapies \u00e0 base d&#039;oligonucl\u00e9otides dans le but de transformer le traitement des maladies neuromusculaires et neurologiques graves, a annonc\u00e9 aujourd&#039;hui sa d\u00e9cision volontaire de suspendre temporairement l&#039;\u00e9tude de phase 2 CONNECT2-EDO51 du PGN-EDO51 chez les patients atteints de dystrophie musculaire de Duchenne (DMD) jusqu&#039;\u00e0 ce que la soci\u00e9t\u00e9 puisse examiner les r\u00e9sultats de la cohorte de 10 mg\/kg dans l&#039;\u00e9tude de phase 2 CONNECT1-EDO51 en cours.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Les deux premi\u00e8res cohortes de l&#039;\u00e9tude CONNECT1 sont enti\u00e8rement recrut\u00e9es et les donn\u00e9es de la cohorte 10 mg\/kg sont attendues au cours du troisi\u00e8me trimestre 2025. Aucun nouveau probl\u00e8me de s\u00e9curit\u00e9 li\u00e9 au PGN-EDO51 n&#039;a \u00e9t\u00e9 observ\u00e9 depuis la derni\u00e8re mise \u00e0 jour de s\u00e9curit\u00e9 de la Soci\u00e9t\u00e9 en date du 23 janvier 2025.<\/p>","protected":false},"excerpt":{"rendered":"<p>PepGen, a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced its voluntary decision to temporarily pause the Phase 2 CONNECT2-EDO51 study of PGN-EDO51 in patients with Duchenne muscular dystrophy (DMD) until the Company can review results from the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":3081,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[281],"tags":[137,275,122,193,194,77,273,274],"class_list":["post-3079","post","type-post","status-publish","format-standard","has-post-thumbnail","category-press-releases","tag-clinical-trial","tag-connect1-edo51","tag-exon-51","tag-exon-51-skipping","tag-exon-51-treatment","tag-exon-skipping","tag-pepgen","tag-pgn-edo51"],"_links":{"self":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3079","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/comments?post=3079"}],"version-history":[{"count":0,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/posts\/3079\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media\/3081"}],"wp:attachment":[{"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/media?parent=3079"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/categories?post=3079"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dmdwarrior.com\/fr\/wp-json\/wp\/v2\/tags?post=3079"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}